Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting an observational study to collect and store tissue and blood samples from patients diagnosed with various types of cancer, including hematopoietic and lymphatic system neoplasms and malignant solid tumors. The aim is to create preclinical models that help scientists better understand cancer and test new treatments. This research is sponsored by the National Cancer Institute LAO and involves patients being treated or evaluated for cancer at participating sites. During the study, tissue and blood samples are collected during clinical procedures that patients are already undergoing as part of their cancer care. These samples are preserved through methods such as xenograft models, where tissue is transplanted into another species, or in vitro cell cultures for future laboratory analysis. There are no experimental treatments given instead, the study focuses on obtaining and storing biological materials. Participants will be involved by allowing collection of their tissue and blood samples during their routine medical procedures. The research team will monitor the procurement of these specimens for up to five years. No additional treatments are administered as part of the study. The primary outcome measured is the successful collection and storage of tissue and blood samples to support future cancer research and model development.
Actively Recruiting
This research evaluates patients with metastatic HER-2-positive breast cancer who are at risk of heart damage from trastuzumab-based treatments. It includes two groups one observational group of patients taking beta blockers, ACE inhibitors, or ARBs alongside their cancer therapy, and a smaller randomized group studying whether carvedilol may prevent heart side effects from chemotherapy. The study aims to understand how often heart problems occur and identify factors that predict these risks. Participants are assigned to one of three groups those taking carvedilol twice daily, those receiving no additional treatment, and those already on beta blockers, ARBs, or ACE inhibitors who are observed without intervention. Treatments or observation continue for up to 108 weeks, with repeated cycles every 12 weeks unless disease progresses or side effects occur. The study also collects blood samples and performs heart function imaging to explore biomarkers and measure heart strain. During the study, participants undergo regular echocardiograms every 12 weeks to assess heart function and strain. Researchers monitor for cardiac events, interruptions in cancer therapy, and adherence to medication. Blood samples are taken to bank for future studies. The main outcome is time until the first sign of cardiac dysfunction over about two years. Safety and side effects of treatments are also tracked, and participants are followed until the study ends in 2031.